Risk factor
Very high price volatility
Profitability factor
Favourable analyst view
About
Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development of novel ribonucleic acid (RNA) therapeutics in hematology, cardiovascular, and other rare and metabolic indications. The company's platform includes mRNAi GalNAc Oligonucleotide Discovery platform designed to accurately target specific disease-associated genes in the liver. It designs short interfering RNA molecules to harness the...
Company Valuation
From both historical and forecast perspectives, the stock is considerably overpriced compared to similar stocks.
Target Price
The average target price of SLN is 32 and suggests 510% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increase
Buy
Sell